Spinosad 0.9% suspension
سوسپانسیون اسپینوساد ۰٫۹٪ (شپش)
🪱 Antiparasitic Products, Insecticides And RepellentsTopical pediculicide
Market / country: 🇺🇸 USA
Natroba (US)
🧮 Dose calculator
Head lice · Regimen source: FDA Natroba · 2.2
- • Up to 120 mL depending on hair length. Repeat if live lice seen after 7 days. In children only with adult supervision. FDA Natroba · 2.2FDA Natroba · 2
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Not recommended under 6 months (benzyl alcohol). FDA Natroba · 8.4
Formulations
- Spinosad 0.9% topical suspension, 120 mL — suspension 🇺🇸 USA FDA Natroba · 3
👥 Special populations
- 🤰 PregnancyNo specific problem stated
Label: minimal systemic absorption; fetal exposure not expected. FDA Natroba · 8.1
“Risk Summary Spinosad, the active ingredient in NATROBA, is not absorbed systemically following topical application, and maternal use is not expected to result in fetal exposure to the drug.”
- 🤱 BreastfeedingNo specific problem stated
Label: infant exposure not expected. FDA Natroba · 8.2
“Topical benzyl alcohol is unlikely to be absorbed through the skin of breastfeeding women in clinically relevant amounts; therefore, breastfeeding is not expected to result in exposure of the infant to NATROBA [ see Clinical Pharmacology (12.3) ].”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Natroba · 8.4
“Head Lice Infestation The safety and effectiveness of NATROBA for the topical treatment of head lice infestation have been established in pediatric patients 6 months of age and older [see Clinical Pharmacology (12.3) and Clinical Studies (14) ] .”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Natroba · 8.5
“Clinical studies of NATROBA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA022408
- DailyMed (FDA label)FDA Natroba
- MedlinePlus (NIH)❌ None
- WHO ATC/DDD❌ None
- Darooyab (Iran)❌ None
🇮🇷 Not found in Iran list Darooyab · search
Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Natroba · 3FDA Natroba · 2.2FDA Natroba · 2FDA Natroba · 8.4FDA Natroba · 8.1FDA Natroba · 8.2FDA Natroba · 8.5FDA Natroba · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · search
- Clinical review⚠ Unverified